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Abstract 
The current methodology for determining  the biological effect of Boron Neutron 
Capture Therapy (BNCT) has recently been questioned, and a more accurate framework 
based in the photon isoeffective dose has been proposed. In this work we derive a first 
order approximation to this quantity than can be easily evaluated even from limited 
data, as is the current situation in the radiobiology of BNCT. This procedure removes 
the main drawbacks of the current method and it is based on new weighting factors that, 
as a difference with the previously used, are true constants (dose independent). In 
addition to this, we apply the formalism to allow the comparison to a fractionated 
conventional radiotherapy treatment, for which there is a lot of knowledge from clinical 
practice. As an application, the photon isoeffective dose of a BNCT treatment for a 
brain tumor is estimated. An excel sheet used for these calculations is also provided as 
supplementary material and can be used also with user-provided input data for the 
estimation of the photon isoeffective dose for comparison with conventional 
radiotherapy, both to single and fractionated treatments.  
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1. Introduction 
Boron Neutron Capture Therapy (BNCT), which has recently shown very promising 
results (Barth et al. 2012), is now facing a renaissance with the introduction of a new 
generation of accelerator based BNCT centers expected soon (Kreiner et al. 2016). 
Since the neutron beam spectrum from an accelerator can change substantially from a 
reactor-based system, a revision of the dose planning procedures is appropriate. 
In current BNCT clinical studies the physical dose is calculated as the sum of 
three contributions: the neutron dose, 𝐷𝑛, the boron dose, 𝐷𝐵, and the gamma dose, 𝐷𝛾. 
The neutron dose is usually separated as: the fast dose, 𝐷𝑓, from the secondary particles 
(mainly hydrogen recoils) produced by neutrons with energy above 0.5 eV and the 
thermal dose, 𝐷𝑡, for neutrons with energy below 0.5 eV (IAEA 2001, Goorley et al. 
2002). The latter is dominated by the 
14
N(n,p) reaction and sometimes it is also called 
the nitrogen dose (Joensuu et al. 2003), although the energy is mainly delivered by the 
ejected proton. The dose contribution from the 2.224 MeV photons from the hydrogen 
capture of thermal neutrons is excluded from 𝐷𝑡 and included in 𝐷𝛾. 
The reason for this separation is to account for the different relative biological 
effectiveness of these contributions, as the total dose is a mix of high and low LET 
products in tissue.Therefore, the "biological" or "weighted" dose (𝐷𝑊) is defined as the 
sum of the dose components weighted with different factors 𝑤𝑖 (IAEA 2001. Joensuu et 
al. 2003), previously called relative biological effectiveness (RBE) factors (Coderre and 
Morris 1999): 
 𝐷𝑤 = 𝑤𝑓𝐷𝑓 +𝑤𝑡𝐷𝑡 + 𝑤𝛾𝐷𝛾 + 𝑤𝐵𝐷𝐵 (1) 
The quantity Dw is interpreted as the equivalent photon dose which produces the 
same effect than the BNCT procedure and is expressed in Gy-Eq or Gy(W). The 
weighting factors 𝑤𝑖 are defined as the ratio of the reference photon irradiation 





,         𝑖 = 𝑡, 𝑓, 𝛾, 𝐵. (2) 
The current 𝑤𝑖 factors were determined in radiobiology experiments, and they 
are assumed as constants, although they depend on the survival fraction (i.e. the doses 
delivered) of those experiments. For example, the common value for 𝑤𝑓 and 𝑤𝑡 of 3.2 
for tumors was obtained for an in-vivo clonogenic gliosarcoma cell survival of 1%, but 
for other survival fractions the values vary from 2.8 to 3.5 (Coderre et al. 1993). The 
photon weighting factor has been taken systematically as one, although there is 
evidence against this value because of the smaller photon dose rate in BNCT (Kiger et 
al. 2008, Hopewell et al. 2011, 2012). The boron weighting factor is a compound-
dependent factor, also called CBE (compound biological effectiveness), which was 
obtained by subtraction from the total beam effect and incorporating the biological 
effect of the rest of components with the assumed values of 𝑤𝑓 and 𝑤𝑡 (Coderre and 
Morris 1999). In this way, any deficiency of the other coefficients could be 
compensated. These factors can be applied reliably to other beams for which the 
different dose terms are similar to the conditions in which this 𝑤𝐵 factor was obtained. 
However, this may not be the case for different neutron beams for the newly-proposed 
accelerator-based neutron sources. In particular, for the first accelerator-based neutron 
source which is performing clinical trials, the C-BENS at Kyoto (Tanaka et al. 2011, 
Ono 2018), it has been reported important differences with respect to the epithermal 
beam from a reactor (Tanaka et al. 2009, Ono 2018). This source, based on the 
9
Be(p,n) 
reaction, shows aspectrum with a maximum at higher epithermal energies than that for a 
typical reactor source, which may lead to a different relative contributions of 𝐷𝑓 and  𝐷𝑡 
at different depths. Also, for the reaction 
7
Li(p,n) near the threshold, which is used in 
some other facilities such as SOREQ (Halfon et al 2009), it has been measured an 
spectrum for which the high energy tail of the spectrum ends sharply below the MeV 
range (Bedogni et al. 2018). This is constrained from the kinematics of the reaction 
which precludes neutron energies in the MeV range, quite different than the tail of 
neutrons from reactors. Therefore, the relative contribution of 𝐷𝑓 can differ. 
In spite of its usefulness in the many clinical trials performed using research 
reactors, there are some drawbacks in the current procedure that can be improved.  First, 
as mentioned, the weighting factors are not constant as they are dose-dependent. The 
reason is that while the biological effect, defined as 𝐸 ≡ − ln 𝑆 where S is the survival 
fraction of cells after irradiation, can be assumed to depend linearly on the dose for high 
LET radiation, for photons the dependence is known to have a linear-quadratic (LQ) 
dependence (Kellerer and Rossi 1974, Chadwick and Leenhouts 1981), as: 
 𝐸 ≡ − ln 𝑆 = 𝛼𝑝𝐷𝑝 + 𝛽𝑝𝐷𝑝
2 (3) 
Therefore, for weighting a high LET radiation dose component 𝐷𝑖 it has to be 
used the factor 𝑤𝑖 = 𝐷𝑝/𝐷𝑖, where 𝐷𝑝 is the reference photon dose required to produce 
the same effect than this particular 𝐷𝑖 value. If this value is used for doses lower than 
the 𝐷𝑖 value chosen to compute 𝐷𝑝, the resulting weighted dose is underestimated, and 
for higher values of 𝐷𝑖, it is overestimated. 
Also, the additivity of the different terms may increase the error in the 
estimation of the equivalent photon dose by the addition of the weighted dose terms as 
illustrated graphically by Gonzalez and Santa Cruz (2012). In order to fix these 
drawbacks, and including other improvements, such as the synergies between different 
dose components, these authors defined the photon isoeffective dose, 𝐷𝑅, which 
represents more accurately the photon dose which produce the same biological effect 
than the BNCT treatment (González and Santa Cruz 2012). It can be calculated from a 
comparison between the biological effects of both the reference photon radiation and a 









𝐷𝑖𝐷𝑗 = 𝛼𝑅𝐷𝑅 + 𝐺(𝜃′)𝛽𝑅𝐷𝑅
2 . (4) 
 
This method takes into account the LQ model for all the dose components, the possible 
synergies between them and the repair mechanisms as a function of time by including 
the Lea-Catcheside time factor, 𝐺(𝜃). This formalism was applied to evaluate previous 
data for BNCT head and neck patients, finding that this isoeffective dose predicts the 
clinical responses better than the current weighted dose formalism (Gonzalez et al. 
2017). 
In this work, we propose a first order approach for the estimation of the photon 
isoeffective dose that can be applied with the common knowledge of the RBE data, but 
introducing the most important corrections required by the use of the radiobiological 
LQ method, which are the quadratic terms of the effect of both the gamma dose 
component in BNCT and the reference photon dose (the own isoeffective dose). For the 
incorporation of the radiobiology data to this method we propose the use of newly 
defined weighting factors which are true constants (i.e. dose-independent).   
2. Methods 
2.1. Formalism for the estimation of the photon iso-effective dose in BNCT  
 Our model consists of a first order approximation to the photon iso-effective 
dose described by Eq. (4) with some simplifying assumptions:  
(i) The quadratic parameters are neglected for the high LET radiation 
components (i.e., 𝛽𝑖 ≅ 0 for 𝑖 = 𝑓, 𝑡, 𝐵), a common aproximation in high LET 
radiobiology  (Bloomer and Adelstein 1982). Previous data from in-vitro irradiation in 
BNCT beams shows survival that follows a quadratic curve, but this includes the effect 
of the gamma component of the beam (normally the main component in those beams). 
Usually, once this component is extracted correctly and only the effect of  high LET 
radiation is represented, it well fit with a linear aproximation that not requires the 
quadratic parameter 𝛽𝑖.With this assumption, synergic effects between different dose 
components are also neglected, an effect that has been estimated to be of a 7% of the 
photon isoeffective dose (González and Santa Cruz 2012). However, the role of the 𝛽𝑖 
coefficients for the gamma component and especially for the reference photon radiation, 
accounts for the most part of the much higher discrepance between the photon 
isoeffective dose and the current formalism of RBE-weighted dose, and they are 
included in the present formalism This approximation is aimed to use available 
experimental data, that is still not conclusive for the synergies (Phoenix et al. 2013). 
(ii) We assume that the radiobiology coefficients for the gamma dose and the 
reference radiation, as being those of photons, are the same, which will be called 𝛼𝑝, 𝛽𝑝 
and can be taken from the extensive literature on the radiobiology of conventional 
radiation therapy. Although this assumption will continue through the formalism 
description, the possibility to include specific parameters for the  BNCT gamma 
component, when data is available, is included later on. 
(iii) For consistency with the use of conventional photon radiobiology data, the 
Lea-Catcheside factor 𝐺(𝜃′) for the reference radiation is assumed to be 1 for a single-
session treatment and 1/𝑛  for a fractionated treatment in  𝑛 sessions where the time 
between sessions is large (Brenner 2008). Additionally, the 𝐺 factor for the gamma 
component of the BNCT treatment is approximated by 1, but if a different value is 
adopted in the future, it can be introduced in our formalism as will be discussed below, 
where it will be also shown how a dose reduction factor for this component, as it has 
been suggested by some authors (Kiger et al. 2008, Hopewell et al. 2011, 2012), can be 
also incorporated. These options allow to consider the different dose rate effect of the 
two photon irradiations under comparison.  
With these assumptions, Eq.(4) is reduced to: 
 𝛼𝑡𝐷𝑡 + 𝛼𝑓𝐷𝑓 + 𝛼𝑝𝐷𝛾 + 𝛽𝑝𝐷𝛾
2+ 𝛼𝐵𝐷𝐵 = 𝛼𝑝𝐷𝑝 + 𝛽𝑝𝐷𝑝
2 , (5) 
where we have denoted as 𝐷𝑝 our approximation to 𝐷𝑅 in order to avoid confusion, but 
it represents an approximation to the photon iso-effective dose, in units of Gy (IsoE). 
The left hand side of the equation represents the biological effect 𝐸 of the BNCT 
treatment, which is defined as the log of the survival fraction 𝑆 of cells: 
 
𝐸 = − ln 𝑆 =  𝛼𝑡𝐷𝑡 + 𝛼𝑓𝐷𝑓 + 𝛼𝑝𝐷𝛾 + 𝛽𝑝𝐷𝛾
2+ 𝛼𝐵𝐷𝐵  (6) 
and the right hand side that of the photon reference irradiation, assumed applied in a 
single session: 
𝐸 = − ln 𝑆 =  𝛼𝑝𝐷𝑝 + 𝛽𝑝𝐷𝑝
2     (7) 
But we can also relate this effect to that produced by a fractionated conventional 
radiation treatment, which is known, taking into account repair mechanisms between 
sessions, described by (Fowler 1990): 
𝐸 = − ln 𝑆 =  𝛼𝑝𝑛𝑑𝑝 + 𝛽𝑝𝑛𝑑𝑝
2 ,            (8) 
Where 𝑛 denotes the number of sessions, and 𝑑𝑝 the dose delivered per fraction. This is 
equivalent to approximate the Lea-Catcheside factor for the fractionated treatment by 
1/𝑛 , as mentioned above. Therefore, either using equation (5) or Eq. (6) combined with 



























)                      (9𝑏)
 
We define new weighting factors as: 
 𝑊𝑖 = 
𝛼𝑖
𝛼𝑝
 , 𝑖 = 𝑡, 𝑓, 𝐵 . (10) 
These are the key factors for the present formalism. Assuming that the dose-
survival curve is well described by the LQ model (only linear for the high LET 
components), the 𝛼 coefficients do not depend on the survival fraction and therefore the 
𝑤𝑖
∗ factors are true constants. They are only specific to the tissue and the biological end-
point. 
Then, Eq.(5) reads:  


















)         (11𝑏)
 
Just for convenience we will denote the left-hand-side of the equation as:  
 
𝐷𝑊




) +𝑊𝐵𝐷𝐵                (12) 
 
So, for finding the photon iso-effective dose of a single session treatment we 
only have to solve the quadratic equation (11a), which gives: 
 𝐷𝑝 = 
𝛼𝑝/𝛽𝑝
2




∗ } ,   (13) 
and, from Eq.(11b), for obtaining the photon isoeffective dose for a fractionated 
treatment, assuming 𝑑𝑝 is known (2 Gy typically), the number of doses of the 









                               (14) 
 
from which the fractionated photon iso-effective dose is just 𝐷𝑝 = 𝑛𝑑𝑝.  In both cases, 
𝐷𝑊
∗  is given by Eq. (8).  
These formulas (13) and (14) allow to estimate the photon iso-effective dose in a 
direct way provided we have information on the new weighting factors, which will be 
discussed below, and the ratio 𝛼𝑝/𝛽𝑝, which is tabulated for a number of cell lines, 
tissues (tumor and normal) and specific effects in organs from the large amount of 
radiobiology data of conventional radiation. These ratios are commonly used in 
conventional radiotherapy for adjusting the fractioning of treatments when the planned 
schedule is altered. This ratio takes large values for tumors and small for normal tissues, 
except in acute response effects. 
 Although the photon isoeffective dose formalism of Eq. (2) was originally 
developed for tumor response, the present approximation given in Eqs. (13) and (14) 
can give also estimations of normal tissue complications provided that the 𝛼𝑝/𝛽𝑝 values 
entered correspond to the biological end-point of interest. The reason is that the right 
hand side of Eq.(11b) represents the well-known biological effective dose (BED) of 
standard radiotherapy, which is used for estimating also normal tissue effects and 
𝛼𝑝/𝛽𝑝 are determined for them. The reliability of the predictions depends on the 
accuracy of the input data. An implicit assumption in the use of Eq. (11b) is that the 
ratio 𝛼𝑝/𝛽𝑝 is the same for the gamma component of the BNCT and a fractionated 
radiotherapy treatment. This could be improved if we know the dose-response of the 
gamma dose in BNCT dose for the effect of interest and we can estimate their 
coefficients 𝛼𝛾, 𝛽𝛾 . If this is the case, Eq. (11a),(11b) should be replaced by:  


















)          (15𝑏)
 
Where 𝑊𝛾 = 𝛼𝛾/𝛼𝑝 , which represents a dose reduction factor (DRF) for the 
gamma dose in BNCT, and 𝐺(𝜃) is the Lea-Catcheside factor for this component. 
Therefore, if future knowledge on these parameters is available from experimentation, 
this formula should be applied. 
2.2. Relation between new weighting factors, 𝑾𝒊 and previous ones, 𝒘𝒊.  
Ideally, the new weighting factors 𝑊𝑖   should be determined from radiobiological 
measurements, obtaining the 𝛼𝑖 coefficient for each dose component by a fitting of the 
function 𝑆𝑖 = 𝑒
−𝛼𝑖𝐷𝑖 to the survival empirical data of  𝑆𝑖 due to this particular dose 
component i. But it is not common to deal with this data as the irradiation always 
contains more than one term, and one has to proceed carefully as how to separate the 
effects of different components, for which data from different type of beams is required. 
An example of this situation will be mentioned in the next section. 
However, and this is the major advantage of this approximation, when we do not 
have the required data on the survival curve, but limited data such as a particular value 
of the previous RBE values obtained for a particular dose component, the current 
method can be applied to estimate the photon isoeffective dose. For this purpose, we 
will obtain now a relationship between the current weighting factors and the newly 
defined ones. 
If 𝐷𝑝𝑖  is the photon dose producing the same effect as a particular dose 
component 𝐷𝑖, then by equating the common effect that corresponds to both doses we 
can express: 
 𝛼𝑖𝐷𝑖 = 𝛼𝑝𝐷𝑝𝑖 + 𝛽𝑝𝐷𝑝𝑖
2 , (16) 








 . (17) 
Identifying 𝑤𝑖 = 𝐷𝑝𝑖/𝐷𝑖 and 𝑊𝑖 = 𝛼𝑖/𝛼𝑝 ,  the following relation is found: 
 𝑊𝑖 = 𝑤𝑖 (1 +
𝐷𝑝𝑖
𝛼𝑝/𝛽𝑝
) , (18a) 
or equivalently, in terms of 𝐷𝑖 we find: 
 𝑊𝑖 = 𝑤𝑖 (1 +
𝑤𝑖𝐷𝑖
𝛼𝑝/𝛽𝑝
) . (18b) 
 According to Eq.(18a), 𝑤𝑖 is a decreasing function of the dose and coincides 
with 𝑊𝑖 in the limit  𝐷𝑝𝑖 → 0, therefore 𝑊𝑖 can be considered as the maximum RBE 
value defined previously (Carabe-Fernández et al. 2010). 
 
3. Results and discussion 
3.1. Estimation of the new weighting factors for brain tumor treatments from 
existing data of 𝒘𝒊.  
3.1.1. Tumor values of 𝑊𝑓 and 𝑊𝑡 
Currently it is assumed that the factors 𝑤𝑓 and 𝑤𝑡 take the same values, that we 
will denote by 𝑤𝑛 and called “pure neutron weighting factor”.  With this assumption, 
we will obtain an estimation of the new neutron weighting factor 𝑊𝑓 = 𝑊𝑡 ≡ 𝑊𝑛. 
However, one should keep in mind that this is not a requirement of the model that can 
be also applied if from new experiments a different value of 𝑊𝑓 than 𝑊𝑡 is obtained. 
The commonly accepted value of 3.2 for tumor was obtained by Coderre et al. 
(1993) studying the biological effectiveness factors from a rat 9L gliosarcoma model. 
The irradiations were performed at a mixed field of neutrons and photons at BMRR. 
However, they also performed X-ray irradiations that allowed them to remove the effect 
of the photon component of the mixed beam (assumed, as in this work, that both 
produce the same dose-response). From the data of the fit of the photon survival that 
these authors performed, which gave the results 𝛼𝑝 = 0.26 ± 0.03 Gy
-1 
and 𝛽𝑝 =
0.003 ± 0.001 Gy-2, and assuming that the survival fraction from the photon 
components is function 𝑆𝛾 = 𝑒
−𝛼𝑝𝐷𝛾−𝛽𝑝𝐷𝛾
2
, we can extract the pure neutron survival 
data as 𝑆𝑛 = 𝑆/𝑆𝛾 , this is illustrated in Table 1. 
 
𝐷 (Gy) 𝑆 𝐷𝛾(Gy) 𝑆𝛾 𝐷𝑛(Gy) 𝑆𝑛 
3 0.2±0.05 0.986 0.771±0.024 2.013 0.259±0.073 
4.1 0.08±0.04 1.349 0.700±0.030 2.751 0.114±0.062 
8.5 0.0014±0.002 2.796 0.472±0.043 5.704 0.003±0.004 
Table 1. Factorization of the survival fraction S of the in-vivo results of Coderre et al (1993) in the 𝑆𝛾 




Then, fitting the data of 𝑆𝑛 as a function of 𝐷𝑛 by the expression 𝑆𝑛 = 𝑒
−𝛼𝑛𝐷𝑛 , 
illustrated if Figure 1, we obtain the result: 𝛼𝑛 = 0.876 ± 0.083 Gy
-1
. Therefore, using 







Figure 1. Plot of the pure neutron 
survival from the measurements 
of Coderre et al. (1993) as a 
function of the neutron dose and 







Obviously, a linear-quadratic term as used in the original paper of Coderre et al 
(1993) would provide a better fit, but as they said, they did it for a mathematical (an 
additional fit parameter) rather than for a physical reason. However, for consistency in 
our model, where the quadratic terms are neglected for the high LET components, we 
have restricted to the abovementioned one-paramter fit, which avoids dealing with a 
parameter with high uncertainty that can have a great impact on the survival for greater 
doses than dose for which data are available.  
3.1.2. Normal tissue values of 𝑊𝑓 and 𝑊𝑡 
The present formalism is not only useful in these cases where we have 
information of the survival curve, but also when there is limited data as the RBE 
calculated at one point. This is the case of the 𝑤𝑡 = 𝑤𝑡 ≡ 𝑤𝑛 factor reported for healthy 
tissue by Morris et al. (1994). In this work, the myelopathy effects on the spinal cord of 
rats (end point 50% incidence) under irradiation with a mixed neutron and photon beam 
was studied. In the absence of 
10
B, they obtained that the same biological effect was 
achieved by 13.58 ± 0.38 Gy of their beam than with 𝐷𝑝 =19.0 ± 0.2 Gy of X-rays, 
taken from Wong et al. (1993). From this observation, a mixed RBE equal to 1.4 was 
derived.  As the dose delivered to the blood in the vasculature of the spinal cord verified 
that 𝐷𝑡 + 𝐷𝑓 ≈ 𝐷𝛾(22), it can be calculated that 𝐷𝑛 = 𝐷𝑡 + 𝐷𝑓 = 6.79 ± 0.19 Gy. We 
apply our formalism for evaluating the 𝑊𝑛 from Eq. (10), which in this particular case 
can be written as: 










from which we find 𝑊𝑛 = 17.3 ± 1.0.  For this calculation we have used the value of 
𝛼𝑝/𝛽𝑝  = 3  Gy,  used in the same paper, from Wong et al. (1993). 
The resulting neutron weighting factor for neutrons and normal tissue is larger 
than for tumor. However, the photon iso-effective dose in normal tissue will remain 
much lower, as it will be seen in Section 3.5. 
In this section we have made the implicit assumption that the concept of photon 
isoeffective dose, originally conceived for describing tumor cell killing, can be also 
applied to the estimation, for normal tissue complications, of the photon dose that 
produce the same effect than the BNCT treatment. This is only valid if all the 
parameters used in Eqs. (12-15) (i.e. the dose-independent weighting factors or those 
parameters used to derive them and the alpha/beta ratio for the reference radiation) 
corresponds to the same biological end-point. The linear quadratic model has been 
extensively used for the description of the radiation effects at organs at risk different 
than cell killing (Emami 2013), and alpha/beta ratios are reported for various effects in 
different tissues and organs (Thames et al. 1990). The rationale beyond our assumption 
lies on the fact that the normal tissue complication probability (NTCP) of critical organs 
is considered as a function of the relative effectiveness of the treatment, defined as 
𝐷𝛤 = 𝐷 (1 +
𝑑
𝛼/𝛽
) =  
1
𝛼
(𝛼𝑛𝑑 + 𝛽𝑛𝑑2),         
 
The exponential of  − 𝛼𝐷𝛤, which appears in the exptression for the NTCP, is the 
reminiscent of the LQ model for cellular survival (Kehwar 2005). So the hypothesis 
underlining our approach for normal tissues is that a similar dependence can be assumed 
for the BNCT treatment, which is fact was assumed by Morris et al. (1994) but with the 
fixed RBE classical approach. 
3.1.3.Tumor value of 𝑊𝐵 for BPA 
The value commonly used in clinical trials (Joensuu et al. 2003) of 𝑤𝐵 = 3.8  
for tumor and the BPA compound was obtained by Coderre et al. (1993), where the 
value of 𝛼𝐵 = 2.32 ± 0.09 Gy
-1 
was found, after removing from the survival curve the 
effect of the neutron beam alone. Using the value of  𝛼𝑝 = 0.26 ± 0.03 Gy
-1  
from 
Table 1 (for the same model) and Eq.(6) we find 𝑊𝐵 = 4.35 ±0.67. 
3.1.4. Normal tissue value of 𝑊𝐵 for BPA 
The commonly accepted value for normal tissue of 𝑤𝐵 for the compound BPA is 1.3 
(Coderre and Morris 1999), which was measured in the experiment of Morris et al. 
(1994). In this work, the same biological end point mentioned in section 3.2 was found 
for a total dose of 13.81 ± 0.49 Gy, of which the boron component was 𝐷𝐵 = 4.93 ± 
0.65 Gy. The partial components for the pure neutron and gamma dose were in this case 
𝐷𝑛 = 𝐷𝛾 = 4.44 ± 0.22 Gy. With the present formalism, using Eq.(11a) and assuming 
𝑊𝑓 = 𝑊𝑡 = 17.3 ± 1.0, 𝛼𝑝/𝛽𝑝  = 3 Gy, we find that  𝑊𝐵 = 10.45 ± 3.46. 
3.1.5. Summary and discussion 
The estimation of the new weighting factors performed with some existing data 
are displayed in Table 2. It is important to remark the high uncertainty, due to the own 
uncertainties of the input data. Therefore, any conclusion from their application should 
be taken with caution, and new measurements with smaller uncertainties are desirable. 
These new measurements can be analysed with the present formalism in order to avoid 
errors from the subtraction of the gamma dose that is always present in neutron 
irradiation. With this aim we have started a campaign of radiobiology measurements for 
different cell lines at a pure cold neutron beam at ILL, with the aim of obtaining 𝑊𝑡 and 
𝑊𝐵 values accurately and studying their tissue dependence. These values are key as they 
are universal (due to thermal neutrons), while 𝑊𝑓 could depend on the particular 
spectrum and should be measured at each BNCT facility. 
 
Factor Tissue Value 
𝑊𝑡  Brain tumor 3.37 ± 0.71 
Normal brain 17.3 ± 1.0 
𝑊𝑓  Brain tumor 3.37 ± 0.71 
Normal brain 17.3 ± 1.0 
𝑊𝐵  Brain tumor 4.35 ± 0.67 
Normal brain 10.45 ± 3.46 
 
Table 2. Estimation of the new weighting factors from current data, as described in the text. 
 
 
3.2. Application for a brain tumor clinical trial. 
In order to illustrate the application of the present formalism, we will consider the 
average dose components applied in a BNCT clinical trial of brain tumours and we will 
compare with a conventional radiotherapy treatment by means of the photon 
isoeffective dose. A typical fractionated conventional treatment with photons delivers a 
total dose of 60 Gy in 30 sessions of 2 Gy. We will assume for the normal brain, 𝛼𝑝/𝛽𝑝 
= 3 Gy (Wong et al. 1993). As an example, we consider a BNCT brain tumor clinical 
trial of 18 patients (Joensuu et al. 2003), where the different dose components are 
reported. The average values from all cases of the normal brain maximum (peak) 
physical doses (in Gy) are: 𝐷𝐵 = 4.46,𝐷𝛾 = 3.86, 𝐷𝑡 = 0.61, and 𝐷𝑓 = 0.17 (Joensuu 
et al. 2003). With the classical procedure, the use of Eq. (1) and the weighting factors: 
𝑤𝑛 = 𝑤𝑓 = 𝑤𝑡 = 3.2 and 𝑤𝐵 = 3.8 tumor/1.3 normal tissue, an equivalent photon dose 
of 𝐷𝑤 = 12.15 Gy-Eq is obtained. This value does not exceed the maximal tolerated 
dose for targets 31–40 mm in diameter of 15 Gy in single-session radiosurgery 
(Lawrence et al. 2010). 
We will now apply the new weighting factors, calculated in the previous 
sections, for this tissue:  𝑊𝑓 = 𝑊𝑡 = 17.3 and 𝑊𝐵 = 10.45 (see Table 3). With these 
data we estimate the single-fraction photon iso-effective dose using Eqs. (9,11) as 
𝐷𝑝 = 12.95 Gy (IsoE). So, we found that, even with our larger values of the weighting 
factors for normal tissue, the dose delivered in BNCT to normal brain would remain 
below the limit, being not far from the weighted dose obtained with the previous 
formalism, 𝐷𝑤 = 12.2 Gy-Eq,  
To illustrate another goal of this work, we can also evaluate the iso-effective 
dose of a fractionated conventional radiation treatment using Eq.(14). This gives a value 
of 𝐷𝑝 = 41.36 Gy (IsoE), which corresponds to a photon treatment of about 21 sessions 
of 2 Gy, a value well below the usual protocols.  
Although the physical dose components at the tumor are not reported in this 
reference (Joensuu et al. 2003), we can also perform an approximate estimation of the 
photon iso-effective dose delivered to the tumor. With the assumption that the 
difference with respect to the maximum dose in normal tissue is due to the boron 
component, we can grossly estimate the physical doses at the tumor as 𝐷𝐵 = 10.6, 
𝐷𝛾 = 3.86, 𝐷𝑡 = 0.61, and 𝐷𝑓 = 0.17, which gives a total tumor physical dose of 15.2 
Gy. Then, the prediction of the current formalism (in this case using 𝑤𝐵 = 3.8) gives a 
weighted dose of 𝐷𝑤 = 46.6 Gy-Eq.  With the present approach, using 𝑊𝑓 = 𝑊𝑡 =
3.37, 𝑊𝐵 = 4.35 and the values 𝛼𝑝 =  0.26 Gy
−1, 𝛽𝑝 = 0.003 Gy
−2 (Coderre et al. 
1993), we estimate a photon iso-effective dose of  𝐷𝑝 = 36.98 Gy (IsoE), for a single 
irradiation and of 𝐷𝑝 = 51.65 (IsoE) for a fractionated treatment, which corresponds to 
roughly 26 sessions. The photon iso-effective dose estimated with the present formalism 
is substantially lower than the RBE-weighted dose. This is in agreement with previous 
results of González and Santa Cruz (2012) for brain and melanoma tumors, González et 
al. (2017) and Sato et al. (2018) for head and neck cancers.  
The comparison to fractionated photon radiotherapy shows the higher selectivity 
of BNCT with respect to conventional radiotherapy: while the tumor receives a 
treatment equivalent to 26 sessions of radiotherapy, the effect on normal brain is similar 
to the one produced by about only 21 sessions.  These results are summarized in Table 
3. However, it must be taken into account that the inhomogeneities in the BNCT 
procedure, mainly due to the boron distribution, are much larger then the dose 
distribution of conventional radiotherapy. Here, as an example for illustrating the 
procedure, only the mean tumor dose has been considered for the comparison, while the 
range of values should be considered also when comparing to a conventional procedure. 
This example of application is illustrated in an excel file associated to this paper 
as supplementary material. Although the 𝑊𝛾 factor is assumed to be one in this 
example, the excel file has the possibility of inserting a different value (a dose reduction 
factor, if applicable). 
 
Table 3: Results of the described example of a BNCT treatment using data from Joensuu et al. (2003) 
with both the current and the new formalism. The photon isoeffective dose 𝐷𝑝 has been obtained from Eq. 
(13), for the single photon equivalent irradiation and from Eq. (14) for the equivalent fractionated 
treatment, in both cases with 𝐷𝑊
∗  given by Eq. (11). They are compared to the previously used weighted 




The radiobiology of BNCT is currently facing a renaissance, in which the concept of 
weighted dose is being replaced by the photon isoeffective dose. In order to calculate 
this quantity from radiobiology data, a formalism based on the LQ model and dose-
independent weighting factors has been proposed. This also allows comparing a BNCT 
Tissue  Dose prescribed  
with photons (Gy) 
Conventional weighted 
dose for the BNCT 
treatment (𝐷𝑊) (Gy-
Eq) 
New method: Iso-effective dose 
for the BNCT treatment (𝐷𝑝) 
(Gy-IsoE) 
Normal brain 
(𝛼𝑝/𝛽𝑝 = 3) 
Fractionated: 60  
(30 sessions of 2 Gy) 
 41.36 
(21 sessions of 2 Gy) 
Single-fraction:  12.2 12.96 
Brain tumor 
 
(𝛼𝑝/𝛽𝑝 = 86.6) 
 
Fractionated: 60  
(30 sessions of 2 Gy) 
 51.58  
(26 sessions of 2 Gy) 
Single-fraction:  46.6 36.98 
treatment to conventional fractionated photon therapy. The newly-defined factors can be 
estimated from the current weighting factors, provided that the biological effect of the 
gamma dose was subtracted using the LQ model. As this is not the case for most of the 
data analysed, we propose that new radiobiology experiments should be carried out, and 
we suggest tabulating the new 𝑊𝑖 factors which are independent of the dose or survival 
fraction. 
In spite of the drawbacks of the currently used formalism, the discrepancies 
between the two methods for the clinical trials performed with reactor-based neutron 
sources are small and the quality of the previous treatments has been confirmed by the 
present calculation. However, this might not be the case for treatments in new neutron 
facilities (e.g. accelerator-based sources for BNCT), where the relative dose 
contributions may change. In any case, improvements in the determination of the 
photon isoeffective dose may lead to a better therapeutic outcome.  It is important to 
keep in mind that there are other sources of uncertainty in BNCT treatments which are 
not the scope of this work, especially the boron distribution both in tumor and in the 
different healthy tissues under the neutron field, which are difficult to quantify and for 
which important research efforts are made for reducing them. 
The main effects that could play a role and have been neglected in this 
formalism are the repair mechanism and the synergies between different components, 
that are not described. They are included in the formalism of the photon isoeffective 
dose of González and Santa Cruz (2012), summarized in Eq. (4). For obtaining the 
parameters involved in this equation, we suggest that experimentation at different set 
ups where the relative dose contribution differ significantly should be performed, in 
order to avoid quasilinear dependence uncertainties. For example, for studying 
synergetic effects irradiation with pure neutrons (or with the higher LET particles 
produced by them), with photons and with both radiations simultaneuosly are required, 
as done in the experiments of Phoenix et al. (2013). However the data available is still 
not conclusive (Phoenix et al. 2013) and more experimentation would be useful for 
quantifying this effect. Therefore we believe that our formalism represents an 
intermediate step towards the formalism of Gonzalez and Santa Cruz (2012), although 
the application of the latter that should be the future goal of BNCT radiobiology and 
that precise experimentation for obtaining the required data with accuracy should be 
performed. For example, a pure neutron beam as the cold neutron line PF1b at Institute 
Laue-Langevin previously mentioned where the gamma contamination is negligible 
could be combined with different gamma-generating media (hydrogen containing) for 
irradiating different cell lines. 
Summarizing, in this model a simple approach to the photon isoeffective dose of 
a BNCT treatment is proposed.  This can be considered as a first order approximation to 
the more accurate formalism of González and Santa Cruz (2012), keeping the simplicity 
of former approaches, but incorporating the LQ model just for the photon dose 
component in BNCT and for the reference photon irradiation, when using Eqs. (9,11) 
for comparison with a single photon irradiation and Eq. (14) for a fractionated 
treatment. The model proposed in the present study utilizes more accurately the 
available radiobiological knowledge, however its predictions should be taken with 
caution until enough data is known to reduce the uncertainties in the response for 
different tissues.  
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Supplementary Material: An excel file, used for the calculations of the photon isoeffective dose 
in Section 3.2 is available as Supplementary Material for this paper. In this file the user 
may introduce his/her own data (dose components, weighting factors and α/β ratios), and 
both the single-fraction and 2 Gy-fraction photon iso-effective dose are calculated. There 
are two sheets for different tissues: the first one for the normal tissue of the example and 
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